Praxis Precision Medicines Reviews Unfavorable Outcomes from PRAX-114 Section 2/3 Monotherapy Aria Examine in Sufferers with Main Depressive Dysfunction
Praxis Precision Medicines, Inc. Aria Examine didn’t obtain statistical significance on the first endpoint Strategic realignment to focus sources on Motion Issues and Epilepsy franchises extends money runway into 2024 BOSTON, June 06, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical firm translating genetic insights into the event of therapies…